OncoMatch/Multiple Myeloma (MM)/TP53 / 17p deletion
Multiple Myeloma (MM)TP53 / 17p deletion Clinical Trials
TP53 mutation and/or 17p13.1 deletion (del17p) occur in approximately 10% of newly diagnosed myeloma and up to 30–40% of relapsed/refractory cases, defining a high-risk feature per IMWG and ISS criteria. Del17p/TP53-altered myeloma has poor outcomes with standard therapy and represents an unmet need. Trials investigate novel combinations including anti-CD38 quadruplets, p53-pathway targeting agents, and CAR-T/bispecific antibody strategies specifically in high-risk cytogenetic myeloma.
Top recruiting TP53 / 17p deletion Multiple Myeloma (MM) trials
Ranked by phase and US site count.
See all trials matched to your profile →Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Emory University
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
M.D. Anderson Cancer Center
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Merck Sharp & Dohme LLC